Clinical Trials Sponsored by Celgene Corporation

Total 7453 results

Celgene

Terminated

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma (EXPECT)

T-cell Non-Hodgkin's Lymphoma

France, United States, Australia, Belgium
Celgene

Completed

Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Celgene

Terminated

First Line Therapy for Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

Canada
Celgene

Completed

Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
Celgene

Completed

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Myelofibrosis | Myeloid Metaplasia | Myelofibrosis With Myeloid Metaplasia

United States, Italy, United Kingdom, Austria, Spain
Celgene

Completed

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Multiple Myeloma

Ukraine, Russian Federation
Celgene

Completed

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (FIRST)

Multiple Myeloma

Korea, Republic of, United States, France, Belgium, Canada, Spain, United Kingdom, Australia, Italy, New Zealand, China, Portugal, Switzerland, Taiwan, Austria, Greece, Germany, Ireland, Sweden
Celgene

Terminated

Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
Celgene

Completed

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Multiple Myeloma

Canada, Denmark, Australia, Belgium, France, Germany, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom, Czechia, Greece
Celgene

Completed

Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

Carcinoma, Renal Cell | Prostatic Neoplasms

United States, United Kingdom
Celgene

Completed

A Research Study for Patients With Prostate Cancer

Prostate Cancer | Metastases
Celgene

Completed

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Neoplasms

United States
Celgene

Terminated

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Neoplasm Metastasis

United States, Australia
Celgene

Terminated

ABI-008 Trial in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Celgene

Completed

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

United States
Celgene

Completed

A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects (DDI)

Healthy | Pharmacology, Clinical

United States
Celgene

Completed

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Carcinoma, Non-Small-Cell Lung | Urinary Bladder Neoplasms | Tumor Virus Infections | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Carcinoma, Transitional Cell | Carcinoma, Pancreatic Ductal

Spain, United States, France, Netherlands
Celgene

Withdrawn

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Sarcoidosis
Celgene

Completed

A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects (AME/FE)

Safety and Pharmacokinetics in Healthy Volunteer Subjects

United States
Celgene

Completed

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma (RACE)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Leukemia, Myelomonocytic, Chronic

United States
Celgene

Completed

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

Peripheral T-cell Lymphoma | Adult T-cell Leukemia-Lymphoma

Japan
Celgene

Completed

A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

Pancreatic Cancer

United States
Celgene

Completed

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

United States, Canada
Celgene

Completed

Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer (FABLOx)

Metastatic Pancreas Adenocarcinoma

United States
Celgene

Completed

A Research Study for Patients With Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell | Neoplasm Metastasis

United States
Celgene

Completed

ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies

Solid Tumors

United States
Celgene

Terminated

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
Celgene

Completed

Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer

Lymphoma | Advanced Solid Tumors

United States
Celgene

Completed

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (Sprint)

Lymphoma, Mantle-Cell | Mantle Cell Lymphoma

France, United Kingdom, Belgium, Spain, Denmark, Germany, Israel, Russian Federation, Italy, Poland, Netherlands, Sweden, Greece, Czechia
Celgene

Completed

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q (MDS-005)

Anemia

United States, Belgium, Spain, United Kingdom, Austria, Canada, Germany, Portugal, France, Australia, Israel, Japan, Italy, Czechia, Poland, Turkey
Celgene

Completed

Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

Healthy Volunteer

United States
Celgene

Completed

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC) (LAPACT)

Pancreatic Neoplasms

Spain, United States, Canada, France, Italy
Celgene

Completed

Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites

Healthy Volunteers

United States
Celgene

Terminated

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

Crohn's Disease

United States, Korea, Republic of, Spain, Netherlands, Belgium, Australia, Austria, Denmark, United Kingdom, Hungary, Israel, Portugal, Canada, Germany, Italy, Croatia, Czechia, Greece, Russian Federation, Serbia, Slovakia, Ukraine, Polan... and more
Celgene

Completed

Observational Study of Quality of Live in Patients With Metastatic Pancreatic Cancer (aLIVE)

Pancreatic Neoplasms

Spain
Celgene

Completed

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

Canada, United States, Taiwan, France, Spain, Greece, Italy, Singapore, Tunisia
Celgene

Completed

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, United Kingdom
Celgene

Completed

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

Healthy

United States
Celgene

Terminated

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Celgene

Completed

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

Colitis, Ulcerative

United States, Canada, Slovakia, Poland, Bulgaria, Hungary
Celgene

Completed

A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005)

Multiple Myeloma

United States, Spain, Austria, Greece, Netherlands, Sweden
Celgene

Withdrawn

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Solid Tumor

United States
Celgene

Withdrawn

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Neoplasms | Hematologic Diseases | Multiple Myeloma | Paraproteinemias | Blood Protein Disorders | Therapeutic Uses | Plasma Cells
Celgene

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects

Healthy Volunteers

United States
Celgene

Completed

Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma

Cancer | Lymphomas

United States
Celgene

Withdrawn

A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

Crohn Disease

United States, Spain, Belgium, Denmark, Canada, Australia, Austria, United Kingdom, Netherlands, Italy, Korea, Republic of, Germany, Portugal, Croatia, Czechia, Greece, Hungary, Israel, Poland, Russian Federation, Serbia, Slovakia, ... and more
Celgene

Completed

A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

Spain, United Kingdom, Switzerland, Australia, Israel, Italy, Poland, France, Belgium, Ireland, Austria, Germany, Ukraine, Greece, Sweden
Celgene

Completed

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Canada

3

Subscribe